<DOC>
	<DOCNO>NCT00857961</DOCNO>
	<brief_summary>Testosterone replacement treatment effective way treat hypogonadism men . Acrux propriety testosterone replacement product , Testosterone MD-Lotion study evaluate pharmacokinetics testosterone MD-Lotion formulations.The study also assess safety product .</brief_summary>
	<brief_title>A Study Pharmacokinetics Testosterone Metered Dose ( MD ) -Lotion Formulations</brief_title>
	<detailed_description />
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male study participant prior document diagnosis hypoandrogenism evidence previously document : Hypothalamic , pituitary testicular disorder Serum testosterone less equal 300 ng/dL Were receive , investigator 's opinion eligible receive treatment hypoandrogenism Body Mass Index ( BMI ) less 35 kg/m^2 Passed required laboratory physical screening test Haemoglobin level screen great equal 13.0 g/dL Adequate venous access leave right arm Able communicate study staff , understand study information sheet sign write Informed Consent form ; willing follow comply study procedures Any significant history allergy and/or sensitivity drug product excipients , include history sensitivity testosterone and/or sunscreens Any clinically significant chronic illness find screen physical exam and/or laboratory test Chronic skin disorder ( e.g . eczema , psoriasis ) likely interfere transdermal drug absorption Men suspect reversible hypoandrogenism ( i.e . due medication , stress ) Any man testosterone therapy contraindicate , include : Known suspected carcinoma ( history carcinoma ) prostate symptom benign prostatic hyperplasia and/or symptom low urinary obstruction , Known suspect carcinoma ( history carcinoma ) breast , Severe liver damage i.e . cirrhosis , hepatitis liver tumour , Active deep vein thrombosis , thromboembolic disorder document history condition , Significant cerebrovascular coronary artery disease , Known suspect sleep apnoea , Hematocrit &gt; 51 % Men clinically significant prostate exam clinically significant elevate serum prostate specific antigen ( PSA ) level , age adjust reference range PSA value . Current history drug alcohol abuse ( 4 standard drink per day and/or abnormal liver function test 3 time upper limit normal range value ) Men take concomitant medication affect sex hormone bind globulin ( SHBG ) testosterone concentration metabolism , cytochrome P450 inducer inhibitor , anticoagulant ( warfarin ) , diabetic medication ( insulin ) , antihistamines Men involve sport screen anabolic steroid Men uncontrolled diabetes ( hemoglobin A1c [ HbA1c ] great equal 10 % ) Men take Investigational Product , receive Investigational Product within 28 day prior screen 5 halflives ( whichever longer ) Any contraindication blood sample Study participant plan surgical procedure course study Study participant partner child bear potential willing use adequate contraception ( i.e . condom ) duration study Study participant whose partner pregnant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>